From novel vaccines and treatments to technology and sciences that change the way we live, COVID-19 is having a lasting impact on how healthcare is delivered. Healthcare providers have been financially challenged as they have been forced to focus their efforts away from elective procedures and, instead, to treating the victims of the pandemic. Further, remote healthcare delivery has jumped to the forefront. This new environment is creating new strategic and business opportunities. The pandemic is also focusing attention on certain risk-shifting and contracting aspects of M&A transactions, making it critical that practitioners keep pace with developments as they occur.
What are the likely near-term and longer-term drivers behind healthcare M&A and strategic partnership transactions? How are industries such as healthcare and medical technology responding to the pandemic and positioning themselves to not only weather the storm but flourish throughout it? How has the COVID-19 pandemic impacted pharma and biotech investment and M&A? How has the COVID-19 pandemic affected how parties approach transactions generally and allocate risk between them?
- Chris Comeau, Partner, Ropes & Gray
- Andrew Kaplan, Principal, Bain Capital Private Equity
- Jennifer Romig, Partner, Ropes & Gray
- Chris Roop, Co-Head of North America Mergers & Acquisitions, J.P. Morgan
- Bjorn Thaler, Chief Financial Officer, One Medical